SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnology✕
Previous Page1314151617181920Next Page
2026-06-17GOVX8-KGeoVax Labs Announces Results of 2026 Annual Meeting and Approval of Warrant Exercise Proposals
GeoVax Labs, Inc. held its annual meeting of stockholders on June 17, 2026, where several key proposals were approved. Stockholders elected a seven-member slate of directors to serve until the next annual meeting, including Randal D. Chase, David A. Dodd, and Nicole Lemerond. Significant focus was placed on equity matt...
Nano CapBiotechnologyOfficer / Director Change
2026-06-17GOSS8-KGossamer Bio Announces Final Results of Convertible Notes Exchange Offer and Consent SolicitationMEDIUM
On June 17, 2026, Gossamer Bio announced the final results of its exchange offer and consent solicitation regarding its 5.00% Convertible Senior Notes due 2027. A total of $181,052,000 in aggregate principal amount of the existing notes was validly tendered, representing approximately 90.5% of the outstanding notes. Fo...
Micro CapBiotechnologyDebt Financing
2026-06-17KLTO8-KGreenland Mines Ltd. Announces $3.75 Million Private Placement of Common StockMEDIUM
On June 15, 2026, Greenland Mines Ltd. entered into a Securities Purchase Agreement with three investors for a private placement of 15,000,000 shares of its common stock. The shares are being sold at a price of $0.25 per share, resulting in total gross proceeds of $3,750,000. The company intends to utilize the net proc...
Nano CapBiotechnologyEquity Offering
2026-06-17HEPA8-KHepion Pharmaceuticals Announces 2026 Annual Meeting Results and Equity Plan Amendment
Hepion Pharmaceuticals, Inc. filed a Current Report on Form 8-K to announce the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders voted on three key proposals. First, they elected five directors to the Board: Gary Stetz (who also serves as Interim CEO), Vincent LoPriore, Michael Pur...
BiotechnologyOfficer / Director Change
2026-06-17ICCC8-KImmuCell Corporation Announces Results of 2026 Annual Meeting of Stockholders
ImmuCell Corporation (Nasdaq: ICCC) held its 2026 Annual Meeting of Stockholders on June 11, 2026. During the meeting, stockholders voted on several key corporate governance matters. Seven directors—Gloria J. Basse, P. Olivier te Boekhorst, Anthony A. Dimarco, Gilles Guillemette, David S. Tomsche, Kathy V. Turner, and ...
Micro CapBiotechnologyOfficer / Director Change
2026-06-17IMA8-KImageneBio 2026 Annual Meeting: Director Elections and Approval of Amended 2025 Equity Incentive Plan
On June 16, 2026, ImageneBio, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders elected David P. Bonita, M.D. and Joseph P. Slattery as Class II directors to serve until the 2029 Annual Meeting. Additionally, stockholders ratified the appointment of PricewaterhouseCoopers LLP as the in...
Micro CapBiotechnologyOfficer / Director Change
2026-06-17INMB8-KINmune Bio Inc. Announces Election of Directors and Approval of Amended Stock Incentive Plan at 2026 Annual MeetingMEDIUM
On June 16, 2026, INmune Bio Inc. held its Annual Meeting of Stockholders where several key proposals were approved. Stockholders elected five directors—David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen—to serve until the next annual meeting. Additionally, the appointment of CBIZ CPAs P.C. as the...
Nano CapBiotechnologyOfficer / Director Change
Sponsored
Previous Page1314151617181920Next Page